drugset / Trial / NCT01559831

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

NCT01559831

Phase 1 Withdrawn Valneva Austria GmbH
NaSingle-groupOpen-label

Summary

IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.

Timeline

Start
2012-06
Primary completion
2012-12
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject IC51 Vaccine 0.5 ml Intramuscular

Indications